Log in

NASDAQ:ITRMIterum Therapeutics Stock Price, Forecast & News

$4.31
+0.29 (+7.21 %)
(As of 05/29/2020 04:00 PM ET)
Add
Compare
Today's Range
$4.01
Now: $4.31
$4.60
50-Day Range
$2.31
MA: $3.28
$4.38
52-Week Range
$1.40
Now: $4.31
$7.65
Volume177,700 shs
Average Volume178,051 shs
Market Capitalization$62.15 million
P/E RatioN/A
Dividend YieldN/A
Beta1.27
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulopenem, a penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of adults in uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. Iterum Therapeutics plc was founded in 2015 and is headquartered in Dublin, Ireland.
Read More
Iterum Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.61 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ITRM
CUSIPN/A
Phone353-1903-8920

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$40,000.00
Book Value($2.89) per share

Profitability

Net Income$-103,130,000.00

Miscellaneous

Employees48
Market Cap$62.15 million
Next Earnings Date8/12/2020 (Estimated)
OptionableNot Optionable

Receive ITRM News and Ratings via Email

Sign-up to receive the latest news and ratings for ITRM and its competitors with MarketBeat's FREE daily newsletter.

Iterum Therapeutics (NASDAQ:ITRM) Frequently Asked Questions

How has Iterum Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Iterum Therapeutics' stock was trading at $2.03 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ITRM shares have increased by 112.3% and is now trading at $4.31. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Iterum Therapeutics?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iterum Therapeutics in the last year. There are currently 2 sell ratings, 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Iterum Therapeutics.

When is Iterum Therapeutics' next earnings date?

Iterum Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for Iterum Therapeutics.

How were Iterum Therapeutics' earnings last quarter?

Iterum Therapeutics PLC (NASDAQ:ITRM) issued its earnings results on Thursday, May, 14th. The company reported ($0.90) earnings per share for the quarter, beating the Zacks' consensus estimate of ($1.34) by $0.44. View Iterum Therapeutics' earnings history.

What price target have analysts set for ITRM?

6 equities research analysts have issued 12 month target prices for Iterum Therapeutics' shares. Their forecasts range from $4.00 to $9.00. On average, they expect Iterum Therapeutics' stock price to reach $7.00 in the next twelve months. This suggests a possible upside of 62.4% from the stock's current price. View analysts' price targets for Iterum Therapeutics.

Has Iterum Therapeutics been receiving favorable news coverage?

Media coverage about ITRM stock has trended somewhat positive recently, according to InfoTrie Sentiment Analysis. The research group scores the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Iterum Therapeutics earned a coverage optimism score of 2.0 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news aboutIterum Therapeutics.

Are investors shorting Iterum Therapeutics?

Iterum Therapeutics saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 309,900 shares, an increase of 5.4% from the April 30th total of 294,100 shares. Based on an average daily volume of 51,100 shares, the short-interest ratio is currently 6.1 days. Currently, 5.1% of the company's stock are short sold. View Iterum Therapeutics' Current Options Chain.

Who are some of Iterum Therapeutics' key competitors?

What other stocks do shareholders of Iterum Therapeutics own?

Who are Iterum Therapeutics' key executives?

Iterum Therapeutics' management team includes the following people:
  • Mr. Corey N. Fishman, Pres, CEO & Director (Age 54)
  • Ms. Judith M. Matthews, Chief Financial Officer (Age 49)
  • Dr. Michael W. Dunne, Chief Scientific Officer (Age 59)
  • Mr. Benjamin M. Pe, VP of Operations

When did Iterum Therapeutics IPO?

(ITRM) raised $80 million in an initial public offering on Friday, May 25th 2018. The company issued 5,300,000 shares at $14.00-$16.00 per share. Leerink Partners and RBC Capital Markets acted as the underwriters for the IPO and Guggenheim Securities and Needham & Company were co-managers.

What is Iterum Therapeutics' stock symbol?

Iterum Therapeutics trades on the NASDAQ under the ticker symbol "ITRM."

Who are Iterum Therapeutics' major shareholders?

Iterum Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Granahan Investment Management Inc. MA (1.67%), Ensign Peak Advisors Inc (1.32%) and UBS Group AG (0.09%). Company insiders that own Iterum Therapeutics stock include Corey N Fishman, David George Kelly, Judith M Matthews, Mark Chin, Michael W Dunne, Patrick J Heron, Paul R Edick and Sofinnova Venture Partners Ix,. View institutional ownership trends for Iterum Therapeutics.

Which major investors are selling Iterum Therapeutics stock?

ITRM stock was sold by a variety of institutional investors in the last quarter, including Ensign Peak Advisors Inc, and Granahan Investment Management Inc. MA. View insider buying and selling activity for Iterum Therapeutics.

Which major investors are buying Iterum Therapeutics stock?

ITRM stock was bought by a variety of institutional investors in the last quarter, including UBS Group AG. Company insiders that have bought Iterum Therapeutics stock in the last two years include Corey N Fishman, David George Kelly, Judith M Matthews, Mark Chin, Michael W Dunne, Patrick J Heron, Paul R Edick, and Sofinnova Venture Partners Ix,. View insider buying and selling activity for Iterum Therapeutics.

How do I buy shares of Iterum Therapeutics?

Shares of ITRM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Iterum Therapeutics' stock price today?

One share of ITRM stock can currently be purchased for approximately $4.31.

How big of a company is Iterum Therapeutics?

Iterum Therapeutics has a market capitalization of $62.15 million and generates $40,000.00 in revenue each year. The company earns $-103,130,000.00 in net income (profit) each year or ($7.10) on an earnings per share basis. Iterum Therapeutics employs 48 workers across the globe.

What is Iterum Therapeutics' official website?

The official website for Iterum Therapeutics is www.iterumtx.com.

How can I contact Iterum Therapeutics?

Iterum Therapeutics' mailing address is BLOCK 2 FLOOR 3 HARCOURT CENTRE HARCOURT STREET, DUBLIN L2, 2. The company can be reached via phone at 353-1903-8920 or via email at [email protected]

This page was last updated on 5/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.